Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Jun 30, 2011
Filed with the SEC on Aug 9, 2011 and accepted by EDGAR at Aug 9, 2011, 20:13 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2011-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2011-04-01 to 2011-06-30 | $114.4m | us-gaap:Revenues |
| Revenue | 6 months2011-01-01 to 2011-06-30 | $188.1m | us-gaap:Revenues |
| Cost of revenue | 3 months2011-04-01 to 2011-06-30 | $5.4m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2011-01-01 to 2011-06-30 | $5.4m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2011-04-01 to 2011-06-30 | $173.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2011-01-01 to 2011-06-30 | $332.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2011-04-01 to 2011-06-30 | $96.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2011-01-01 to 2011-06-30 | $168.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2011-04-01 to 2011-06-30 | −$165.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2011-01-01 to 2011-06-30 | −$325.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2011-04-01 to 2011-06-30 | $7.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2011-01-01 to 2011-06-30 | $19.0m | us-gaap:InterestExpense |
| Income tax | 3 months2011-04-01 to 2011-06-30 | $24.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2011-01-01 to 2011-06-30 | $24.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2011-04-01 to 2011-06-30 | −$174.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months2011-01-01 to 2011-06-30 | −$350.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2011-04-01 to 2011-06-30 | −$0.85 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2011-01-01 to 2011-06-30 | −$1.72 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2011-04-01 to 2011-06-30 | −$0.85 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2011-01-01 to 2011-06-30 | −$1.72 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2011-04-01 to 2011-06-30 | 204,413,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2011-01-01 to 2011-06-30 | 203,377,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2011-01-01 to 2011-06-30 | −$402.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2011-01-01 to 2011-06-30 | $15.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2011-06-30 | $458.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2011-06-30 | $827.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2011-06-30 | $1.76bn | us-gaap:Assets |
| Current liabilities | At period end2011-06-30 | $479.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2011-06-30 | $1.31bn | us-gaap:Liabilities |
| Long-term debt | At period end2011-06-30 | $105.0m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2011-06-30 | $307.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001047469-11-007153. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.